Garcia 2004.

Methods	Randomized controlled trial Duration: recruitment between January 1997 and March 1999. Follow up for 6 months.
Participants	Number: 120 enrolled (61 male, 59 female) Inclusion criteria: adults with fewer than 20 viable parenchymal cysts plus 1 or more seizures in the previous 6 months Exclusion criteria: primary generalized seizures, history of antiparasitic treatment, evidence on CT of other diseases, moderate or severe intracranial hypertension, status epilepticus, focal neurological deficits, unstable vital signs, impending risk of death, or pregnancy. Type of lesion: viable
Interventions	Group 1. Albendazole: 400 mg every 12 hours and 2 mg dexamethasone every 8 hours for 10 days Group 2. Placebos
Outcomes	Included in the review: recurrence of seizures during months 2 to 30; partial seizures in month 1, months 2 to 12 and months 13 to 30, and following tapering of anti‐epileptic drugs; seizures with generalization in month 1, months 2 to 12 and months 13 to 30, and following tapering of anti‐epileptic drugs; number of cysts at baseline and 6 months; persistence of seizures at 6 months; adverse events associated with treatment
Notes	Location: Peru Source of funding: not stated
Risk of bias
Bias	Authors' judgement	Support for judgement
Adequate sequence generation?	Low risk	Random assignment in blocks of 6 according to a pre‐established list taken from a random‐numbers table
Allocation concealment?	Low risk	Randomization performed from remote site by a statistician not otherwise involved in the study. All drugs and placebos were administered by the study personnel, who received them in sealed, opaque, sequentially numbered envelopes
Blinding? All outcomes	Low risk	Blinded all study participants and personnel
Incomplete outcome data addressed? All outcomes	Low risk	120 randomized, 116 received study medication, 2 were excluded from the analysis, 14 lost to follow up (100/120 = 83%). The reasons for all withdrawals were clearly documented.
Free of selective reporting?	Low risk	No evidence of selective reporting
Free of other bias?	Low risk	No evidence of other bias